The aim of this study is to validate uHear™, an iOS-based tool, as a screening tool to detect significant hearing impairment as part of a comprehensive geriatric assessment in patients aged 70 years and older. The pass or fail screening cut-off is defined as having two or more consecutive hearing grades starting from the moderate-severe threshold zone ranging from 0.5 - 2.0 kHz.

Inclusion Criteria:

• Patients should have reached the age of 70 or more at enrolment
• Histologically confirmed diagnosis of solid cancer or hematologic malignancy. All stages of cancer are eligible
• Patients should be fluent in Dutch or French
• Patients must receive their primary oncology care in the participating hospital
• Patients should be cognitively capable of performing the audiology assessment
• Patients should be scheduled to receive a CGA
• Patients should have signed informed consent

Exclusion Criteria:

• Patients who do not match the above inclusion criteria
• Patients presenting with clinically diagnosed Meniere's disease, retrocochlear hearing loss, autoimmune inner ear disease, fluctuating hearing loss or a history of sudden sensory neural hearing loss
• Patients who already have a hearing aid or a previously diagnosed hearing loss

This trial will recruit older patients with a minimum age of 70 years old who have been diagnosed with a solid tumour or hematologic malignancy, who are eligible for an oncogeriatric evaluation.